Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Anesthesiology ; 115(4): 743-53, 2011 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-21857500

RESUMEN

BACKGROUND: Buprenorphine, a partial µ-opioid receptor agonist and κ-opioid receptor antagonist, is an effective analgesic. The effects of buprenorphine on sleep have not been well characterized. This study tested the hypothesis that an antinociceptive dose of buprenorphine decreases sleep and decreases adenosine concentrations in regions of the basal forebrain and pontine brainstem that regulate sleep. METHODS: Male Sprague Dawley rats were implanted with intravenous catheters and electrodes for recording states of wakefulness and sleep. Buprenorphine (1 mg/kg) was administered systemically via an indwelling catheter and sleep-wake states were recorded for 24 h. In additional rats, buprenorphine was delivered by microdialysis to the pontine reticular formation and substantia innominata of the basal forebrain while adenosine was simultaneously measured. RESULTS: An antinociceptive dose of buprenorphine caused a significant increase in wakefulness (25.2%) and a decrease in nonrapid eye movement sleep (-22.1%) and rapid eye movement sleep (-3.1%). Buprenorphine also increased electroencephalographic delta power during nonrapid eye movement sleep. Coadministration of the sedative-hypnotic eszopiclone diminished the buprenorphine-induced decrease in sleep. Dialysis delivery of buprenorphine significantly decreased adenosine concentrations in the pontine reticular formation (-14.6%) and substantia innominata (-36.7%). Intravenous administration of buprenorphine significantly decreased (-20%) adenosine in the substantia innominata. CONCLUSIONS: Buprenorphine significantly increased time spent awake, decreased nonrapid eye movement sleep, and increased latency to sleep onset. These disruptions in sleep architecture were mitigated by coadministration of the nonbenzodiazepine sedative-hypnotic eszopiclone. The buprenorphine-induced decrease in adenosine concentrations in basal forebrain and pontine reticular formation is consistent with the interpretation that decreasing adenosine in sleep-regulating brain regions is one mechanism by which opioids disrupt sleep.


Asunto(s)
Adenosina/metabolismo , Analgésicos Opioides/farmacología , Química Encefálica/efectos de los fármacos , Buprenorfina/farmacología , Sueño/efectos de los fármacos , Sueño/fisiología , Animales , Compuestos de Azabiciclo/farmacología , Conducta Animal/efectos de los fármacos , Ritmo Delta/efectos de los fármacos , Electroencefalografía/efectos de los fármacos , Eszopiclona , Hipnóticos y Sedantes/farmacología , Masculino , Microdiálisis , Dimensión del Dolor/efectos de los fármacos , Piperazinas/farmacología , Polisomnografía/efectos de los fármacos , Puente/efectos de los fármacos , Puente/metabolismo , Ratas , Ratas Sprague-Dawley , Formación Reticular/efectos de los fármacos , Formación Reticular/metabolismo , Sustancia Innominada/efectos de los fármacos , Sustancia Innominada/metabolismo , Vigilia/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA